Departamento de Ciências do Comportamento, ICBAS-Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Rua Jorge de Viterbo Ferreira, 228, 4050-313 Porto, Portugal.
CINTESIS-Centro de Investigação em Tecnologias e Serviços de Saúde, R. Dr. Plácido da Costa, 4200-450 Porto, Portugal.
Int J Environ Res Public Health. 2022 May 9;19(9):5768. doi: 10.3390/ijerph19095768.
An early, extensive, accurate, and cost-effective clinical diagnosis of neurocognitive disorders will have advantages for older people and their families, but also for the health and care systems sustainability and performance. BRAINCODE is a technology that assesses cognitive impairment in older people, differentiating normal from pathologic brain condition, based in an EEG biomarkers evaluation. This paper will address BRAINCODE's pilot design, which intends to validate its efficacy, to provide guidelines for future studies and to allow its integration on the SHAPES platform. It is expected that BRAINCODE confirms a regular clinical diagnosis and neuropsychologic tests to discriminate 'normal' from pathologic cognitive decline and differentiates mild cognitive impairment from dementia in older adults with/without subjective cognitive complains.
早期、广泛、准确且具有成本效益的神经认知障碍临床诊断将有利于老年人及其家庭，也有利于医疗保健系统的可持续性和绩效。BRAINCODE 是一种评估老年人认知障碍的技术，基于 EEG 生物标志物评估，可区分正常和病理性大脑状况。本文将介绍 BRAINCODE 的试点设计，旨在验证其疗效，为未来的研究提供指导，并允许其集成到 SHAPES 平台上。预计 BRAINCODE 将通过定期临床诊断和神经心理学测试来区分“正常”与病理性认知下降，并区分有/无主观认知抱怨的老年人的轻度认知障碍与痴呆。
